These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37288777)

  • 1. Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases.
    Lee JM; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
    J Surg Oncol; 2023 Sep; 128(4):549-559. PubMed ID: 37288777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study.
    Hirokawa F; Ueno M; Nakai T; Kaibori M; Nomi T; Iida H; Tanaka S; Komeda K; Hayami S; Kosaka H; Hokuto D; Kubo S; Uchiyama K
    J Gastrointest Surg; 2022 Apr; 26(4):772-781. PubMed ID: 34664190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
    Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases.
    Ninomiya M; Emi Y; Motomura T; Tomino T; Iguchi T; Kayashima H; Harada N; Uchiyama H; Nishizaki T; Higashi H; Kuwano H
    Int J Clin Oncol; 2021 Dec; 26(12):2255-2264. PubMed ID: 34519930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer?
    Hirokawa F; Asakuma M; Komeda K; Shimizu T; Inoue Y; Kagota S; Tomioka A; Uchiyama K
    Surg Today; 2019 Jan; 49(1):82-89. PubMed ID: 30255329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection.
    Zhong W; Xu B; Lu Y; Chang J; Xu L; Zhao H; Che X
    J Gastroenterol Hepatol; 2024 May; 39(5):908-919. PubMed ID: 38323685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- A retrospective, propensity score matching analysis.
    Chen FL; Wang YY; Liu W; Xing BC
    Front Oncol; 2022; 12():973418. PubMed ID: 36132151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
    Yonekawa Y; Uehara K; Mizuno T; Aiba T; Ogura A; Mukai T; Yokoyama Y; Ebata T; Kodera Y; Nagino M
    Int J Clin Oncol; 2021 Jan; 26(1):126-134. PubMed ID: 33074351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma?
    Bernardi L; Roesel R; Aghayan DL; Majno-Hurst PE; De Dosso S; Cristaudi A
    Cancer Treat Rev; 2024 Mar; 124():102696. PubMed ID: 38335813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes of Perioperative Versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: An International Multicentre Propensity-Score Matched Analysis with Stratification by Contemporary Risk-Scoring.
    Di Martino M; Primavesi F; Syn N; Dorcaratto D; de la Hoz Rodríguez Á; Dupré A; Piardi T; Rhaiem R; Blanco Fernández G; de Armas Conde N; Rodríguez Sanjuán JC; Fernández Santiago R; Fernández-Moreno MC; Ferret G; López Ben S; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E
    Ann Surg Oncol; 2022 Oct; 29(11):6829-6842. PubMed ID: 35849284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis.
    Ono K; Abe T; Oshita A; Sumi Y; Yano T; Okuda H; Kurayoshi M; Kobayashi T; Ohdan H; Noriyuki T; Nakahara M
    World J Surg Oncol; 2021 Apr; 19(1):97. PubMed ID: 33820549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D; Hollande F; Michael M; Hayes I; Heriot A; Knowles B; Thomson B
    ANZ J Surg; 2021 Jun; 91(6):1196-1202. PubMed ID: 33543551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis.
    Wang Y; Wen N; Xiong X; Lu J; Li B; Cheng N
    World J Surg Oncol; 2023 Sep; 21(1):276. PubMed ID: 37658360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncological outcomes of neoadjuvant chemotherapy in patients with resectable synchronous colorectal liver metastasis: A result from a propensity score matching study.
    Jiang YJ; Zhou SC; Chen JH; Liang JW
    Front Oncol; 2022; 12():951540. PubMed ID: 36330479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of Perioperative Chemotherapy Does Not Influence Long-Term Outcome of Patients Undergoing Combined Laparoscopic Colorectal and Liver Resection in Selected Upfront Resectable Synchronous Liver Metastases.
    Ratti F; Fuks D; Cipriani F; Gayet B; Aldrighetti L
    World J Surg; 2019 Dec; 43(12):3110-3119. PubMed ID: 31451846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
    Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
    Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
    Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
    Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.